Principal Financial Group Inc. Has $43,000 Stock Holdings in Savara Inc (NASDAQ:SVRA)

Principal Financial Group Inc. decreased its position in Savara Inc (NASDAQ:SVRA) by 42.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,188 shares of the company’s stock after selling 7,607 shares during the quarter. Principal Financial Group Inc.’s holdings in Savara were worth $43,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. ProShare Advisors LLC increased its stake in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after purchasing an additional 2,114 shares during the period. Vanguard Group Inc. increased its position in Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after buying an additional 148,673 shares during the period. CANADA LIFE ASSURANCE Co bought a new position in Savara in the 1st quarter worth approximately $35,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Savara by 15.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after buying an additional 4,625 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after acquiring an additional 746,407 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Price Performance

SVRA opened at $3.46 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market capitalization of $593.81 million, a P/E ratio of -8.05 and a beta of 1.02. The company’s 50 day simple moving average is $3.73 and its 200-day simple moving average is $4.10. Savara Inc has a one year low of $2.82 and a one year high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Sell-side analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Savara

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on SVRA. HC Wainwright cut their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.